Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls

Agnes J Staal-van den Brekel, Annemie M W J Schols, Mieke A Dentener, Guul P M ten Velde, Wim A Buurman, Emiel F M Wouters

Abstract

Background – Weight loss is a frequently occurring problem in patients with lung cancer due to an increased resting energy expenditure (REE) and a decreased energy intake. The aim of the present study was to compare the metabolic and inflammatory characteristics of patients with small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). The metabolic parameters of the lung cancer population were compared with those of a healthy control group.

Methods – REE was measured in 66 patients with lung cancer, subdivided according to their histology, and in 33 healthy controls matched for sex, age, and fat free mass (FFM). Inflammatory mediators were measured in the plasma of the patients with lung cancer.

Results – An increased REE adjusted for FFM was found in the patients with lung cancer. Those with small cell lung carcinoma (SCLC) had an increased REE adjusted for FFM (mean 1925 kcal/day) compared with those with non-small cell lung carcinoma (NSCLC) (mean 1789 kcal/day, 95% CI for difference 36 to 236). FFM accounted for 69% and 48% of the inter-individual variation in REE in controls and those with NSCLC, respectively, while FFM accounted for only 25% of the variation in REE in patients with SCLC in whom the fat mass (FM) also contributed significantly (28%) to the variation in REE.

Increased concentrations of soluble TNF-receptor 75 (sTNF-R75) and cortisol were found in patients with SCLC compared with those with NSCLC. Lipopolysaccharide binding protein (LBP) and sTNF-R55 were related to plasma levels of cortisol.

Conclusion – An enhanced REE adjusted for FFM occurred in patients with SCLC compared with those with NSCLC.

(Thorax 1997;52:338–341)

Keywords: resting energy expenditure, small cell lung cancer, inflammation.

Methods

PATIENTS AND HEALTHY CONTROLS

Thirty three patients with SCLC, 33 with NSCLC, and 33 healthy controls were included in the study. The three groups were matched for sex, age, and fat free mass (FFM). All patients had histologically documented tumours and had not yet received treatment. The exclusion criteria for the study were previous treatment with chemotherapy or radiotherapy, treatment with high doses of corticosteroids, severe endocrine abnormalities (insulin dependent diabetes mellitus, hyper-thyroidism), and body temperature exceeding 37.7°C. Tumour stage was assessed according to the international staging system for lung cancer. The TNM classification was used for NSCLC and the two stage classification system was used for SCLC.

Healthy controls had a stable weight for more
than one year, a body mass index (BMI) of <30 kg/m², a normal body temperature, and no evidence of physical or mental disease as assessed by physical examination. The study was approved by the medical ethical committee of the University Hospital of Maastricht. Informed consent was obtained from all patients and controls.

RESTING ENERGY EXPENDITURE (REE) AND BODY COMPOSITION
REE was measured by indirect calorimetry using a ventilated hood system (Oxycon β, Mijnhardt, Bunnik, The Netherlands) as described previously. Measurements in patients were made at the metabolic ward over a 20 minute period between 07.00 hours and 09.00 hours under quiet conditions after an overnight fast in the hospital while at complete rest. Measurements in control subjects were performed similarly but on an outpatient basis. Variations due to limited physical activities do not significantly influence the measurement of REE. Body composition was assessed by bioelectrical impedance analysis as described previously.

Weight loss was calculated as the difference between the reported stable weight before the illness (six months prior to investigation) and the actual weight. The control group had been weight stable for more than one year before levels. An analysis of covariance was therefore performed similarly but on an outpatient basis. Variations due to limited physical activities do not significantly influence the measurement of REE.

The adjusted REE was calculated as the group mean REE plus measured REE minus predicted REE. The group REE is the mean absolute REE (n = 99), the measured REE is the resting metabolic rate in each subject, and the predicted REE is the calculated energy expenditure obtained by using the individual FFM in the linear regression equation of REE on FFM generated in the control group. Measured REE was also compared with predicted REE using the Harris-Benedict equations in order to allow comparison between this study and previous studies on REE in cancer patients. Subjects with a measured REE above 110% of that predicted by the Harris-Benedict formula were arbitrarily considered hypermetabolic.

MEASUREMENT OF INFLAMMATORY MEDIATORS
Blood was obtained by venepuncture before breakfast. Plasma was separated by centrifugation and stored at −70°C until analysis. Inflammatory mediators were measured using sandwich ELISA and CRP was measured by turbidimetry. The detection limit of the assay was 5 μg/ml. We were not able to measure inflammatory mediators in plasma of the control group, but in a previous study control samples were obtained from 26 healthy elderly individuals. The mean (SD) values of the inflammatory mediators in plasma of healthy controls were as follows: sTNF-R55 1.0 (0.3) ng/ml; sTNF-R75 1.1 (0.4) ng/ml; LBP 8.6 (3.1) μg/ml, CRP <5 μg/ml and TNF-α was not detectable.

BIOCHEMICAL PARAMETERS
Thyroid stimulating hormone was assessed with an immunoradiometric assay and cortisol was determined by a radioimmunoassay. Plasma creatinine levels were used as a renal function parameter and were detected by the modified Jassé reaction (Dimension, Dupont, France).

PULMONARY FUNCTION
Forced expiratory volume in one second (FEV₁) and inspiratory vital capacity (IVC) were measured with a wet spirometer (Pulmonet III; Gould Godart, Bilthoven, The Netherlands). The highest value of at least three technically acceptable spirometric manoeuvres was used and the values were expressed as percentages of the reference values.

ANALYSIS OF DATA
Statistical analyses were performed using the Student’s t test when appropriate, adjusted for multiple testing according to the method of Bonferroni. The Mann-Whitney U test was used for non-parametric data. Since impaired renal clearance leads to increased concentrations of sTNF receptor, the plasma concentrations of sTNF-R55 and sTNF-R75 were analysed together with serum creatinine levels. An analysis of covariance was therefore performed using plasma creatinine levels as a covariable with sTNF-R55 and sTNF-R75 as factors in the statistical model. Frequency data were compared using the χ² test. Correlations were determined using the Pearson correlation coefficient. Results are presented as mean (SD), p values of <0.05 were considered statistically significant. The statistical calculations were performed using the SPSS/PC + 4.0 package.

RESULTS
BASELINE CHARACTERISTICS
Each group consisted of 24 men and nine women (table 1). No differences were found in body weight or BMI among the three groups. Ten patients with SCLC and 11 with NSCLC presented with more than 10% weight loss from their pre-illness weight. No significant differences in lung function parameters were found between the two groups of cancer patients. Cortisol concentrations were significantly enhanced in patients with SCLC compared with those with NSCLC (table 1), although the mean concentration of cortisol was within the normal range (200–700 nmol/l).

RESTING ENERGY EXPENDITURE
REE adjusted for FFM was significantly higher in patients with lung cancer than in healthy controls (mean difference 214 kcal/day, 95% CI 133 to 295; table 2). When the lung cancer population was divided according to tumour type REE adjusted for FFM was significantly higher in those with SCLC than in those with...
Levels of sTNF-R75 were significantly increased in the patients with SCLC compared with those with NSCLC (mean difference 0.7 ng/ml, 95% CI 0.1 to 1.3), but no difference was seen in levels of sTNF-R55, LBP, or CRP, while TNF-α was not detectable (table 3). The levels of sTNF-R55 and LBP were related to cortisol levels (*r=0.42, p<0.01; *r=0.52, p<0.001, respectively). No significant correlation was found for sTNF-R75 (*r=0.20) or CRP (*r=0.33).

**Discussion**

The aim of this study was to compare the metabolic and inflammatory characteristics of patients with lung cancer subdivided according to tumour type. An enhanced REE adjusted for FFM was found in patients with SCLC compared with those with NSCLC matched for sex, age, and FFM. In addition, patients with lung cancer had an increased REE adjusted for FFM compared with healthy controls matched for sex, age, and FFM.

An increase in REE compared with predicted values has been reported previously in patients with lung cancer. Although total energy expenditure is the sum of REE, diet induced thermogenesis, and activity related energy consumption, most studies have focused on REE measurements. Few studies have looked at the occurrence of hypermetabolism in patients with SCLC. Jeb et al. recently found an enhanced REE adjusted for FFM in patients with SCLC but they did not investigate possible reasons for the enhanced REE. Patients with SCLC had an increased REE adjusted for FFM compared with those with NSCLC and healthy controls.

Subdivision of SCLC according to tumour stage revealed that tumour stage did not influence metabolic parameters in SCLC as confirmed by Russell et al. To investigate the clinical relevance of the observed increase in REE to the pathogenesis of weight loss in lung cancer, the expected weight loss over a six month period was calculated. A recently developed computer simulation model was used to calculate the expected weight change in a man aged 65 years of height 170 cm and weight 65 kg with REE amounting to 113% of predicted. It was found that an increase in REE of this amount would result in a weight loss of 7% which corresponds well with the results of this study.

In order to explain the differences in REE, factors contributing to REE were investigated. Firstly, the influence of body composition on REE was analysed. FFM accounted for 69% and 48% of the interindividual variation in REE in controls and patients with NSCLC, respectively, while FFM accounted for only 25% of the variation in REE in patients with SCLC. However, FM accounted for 28% of the variation in REE in patients with SCLC and was a significant covariate in the significant difference in REE observed between patients with NSCLC and those with SCLC. These findings could indicate changes in carbohydrate

**Inflammatory mediators**

**Table 1** Mean (SD) study parameters of the three groups

<table>
<thead>
<tr>
<th></th>
<th>SCLC (n = 33)</th>
<th>NSCLC (n = 33)</th>
<th>Controls (n = 33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M/F</td>
<td>24/9</td>
<td>24/9</td>
<td>24/9</td>
</tr>
<tr>
<td>Age (years)</td>
<td>63 (10)</td>
<td>65 (10)</td>
<td>66 (8)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>69.7 (11.6)</td>
<td>68.9 (11.0)</td>
<td>73.8 (10.7)</td>
</tr>
<tr>
<td>FFM (kg)</td>
<td>48.6 (6.0)</td>
<td>48.7 (5.9)</td>
<td>51.0 (7.1)</td>
</tr>
<tr>
<td>FM (kg)</td>
<td>21.1 (8.4)</td>
<td>20.3 (7.8)</td>
<td>22.7 (7.5)</td>
</tr>
<tr>
<td>Weight loss &gt;10% (n)</td>
<td>10</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.4 (3.2)</td>
<td>23.8 (3.6)</td>
<td>25.4 (3.2)</td>
</tr>
<tr>
<td>Weight loss (%)</td>
<td>62 (6.0)</td>
<td>50.7 (7.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>3.3 (3.6)</td>
<td>3.6 (2.3)</td>
<td>NT</td>
</tr>
<tr>
<td>Cortisol (nmol/l)</td>
<td>569 (179)</td>
<td>570 (170)</td>
<td>NT</td>
</tr>
<tr>
<td>IVC (%)</td>
<td>86.6 (23.4)</td>
<td>93.2 (18.0)</td>
<td>NT</td>
</tr>
<tr>
<td>FFM (%)</td>
<td>76.3 (24.8)</td>
<td>75.3 (23.2)</td>
<td>NT</td>
</tr>
<tr>
<td>Tumour stage (SCLC)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I and II (n)</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage III (n)</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage IV (n)</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumour stage (NSCLC)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limited</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extensive</td>
<td>23</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SCLC = small cell lung carcinoma, NSCLC = non-small cell lung carcinoma, FFM = fat free mass; FM = fat mass; n = number of subjects; BMI = body mass index; TSH = thyroid stimulating hormone; IVC = inspiratory vital capacity; FFM = forced expiratory volume in one second; NT = not tested.

* p<0.05, SCLC versus NSCLC.

**Table 2** Comparison of mean (SD) metabolic parameters between the three groups

<table>
<thead>
<tr>
<th></th>
<th>Total patients (n = 66)</th>
<th>SCLC (n = 33)</th>
<th>NSCLC (n = 33)</th>
<th>Controls (n = 33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>REE (kcal/day)</td>
<td>1691 (255)*</td>
<td>1758 (270)‡</td>
<td>1624 (224)</td>
<td>1546 (248)</td>
</tr>
<tr>
<td>Adjusted REE (kcal/day)</td>
<td>1857 (213)**</td>
<td>1925 (230)†††</td>
<td>1789 (162)‡‡</td>
<td>1643 (138)</td>
</tr>
<tr>
<td>REE (%HB)</td>
<td>120 (10)**</td>
<td>124 (14)‡‡‡</td>
<td>116 (14)</td>
<td>105 (9)</td>
</tr>
</tbody>
</table>

REE = resting energy expenditure; HB = Harris Benedict.

* p<0.01, ** p<0.001, total group versus controls; † p<0.025, ‡ p<0.01, SCLC versus NSCLC; ‡‡ p<0.005, ‡‡‡ p<0.01, SCLC versus controls; ¶ p<0.001, NSCLC versus controls.

**Table 3** Mean (SD) concentrations, medians and range of patients with small cell carcinoma (SCLC) and those with non-small cell lung carcinoma (NSCLC)

<table>
<thead>
<tr>
<th></th>
<th>SCLC (n = 23)</th>
<th>NSCLC (n = 23)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>sTNF-R55 (ng/ml)*</td>
<td>1.6 (0.9)</td>
<td>1.2 (0.7)</td>
<td>0.10</td>
</tr>
<tr>
<td></td>
<td>1.4</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.4–3.9</td>
<td>0.3–3.0</td>
<td></td>
</tr>
<tr>
<td>sTNF-R75 (ng/ml)*</td>
<td>2.3 (1.3)</td>
<td>1.6 (0.4)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td>2.0</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.8–5.4</td>
<td>1.0–2.2</td>
<td></td>
</tr>
<tr>
<td>LBP (μg/ml)</td>
<td>18.9 (8.0)</td>
<td>17.4 (12.1)</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>18.1</td>
<td>15.1</td>
<td></td>
</tr>
<tr>
<td>CRP (μg/ml)</td>
<td>8.4–43.5</td>
<td>3.0–46.9</td>
<td>0.82</td>
</tr>
<tr>
<td></td>
<td>34 (36)</td>
<td>34 (36)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5–145</td>
<td>5–145</td>
<td></td>
</tr>
</tbody>
</table>

* Analysis of covariance adjusted for plasma creatinine. sTNF-R55, sTNF-R75 = soluble TNF receptors 55 and 75; LBP = lipopolysaccharide binding protein; CRP = C reactive protein.

NSCLC (mean difference 136 kcal/day, 95% CI 36 to 236).

FFM accounted for 69% (p<0.001) and FM for 7% (p=0.01) of the interindividual variation in REE in the healthy control group. In the NSCLC population FFM accounted for 48% (p<0.001) and FM for 3% (p=0.05) of the interindividual variation in REE. However, in the SCLC population the prediction of REE by body composition showed a different pattern with FFM accounting for only 25% (p=0.01) of the interindividual variation in REE while FM accounted for 28% (p=0.001).

**Effect of tumour stage**

To investigate the influence of tumour stage in SCLC the patients were divided into those with limited disease (n = 10) and those with extensive disease (n = 23) (data not shown). No differences could be detected in metabolic parameters between the two populations.
Metabolism in SCLC and NSCLC

341

Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls.

A J Staal-van den Brekel, A M Schols, M A Dentener, G P ten Velde, W A Buurman and E F Wouters

Thorax 1997 52: 338-341
doi: 10.1136/thx.52.4.338

Updated information and services can be found at:
http://thorax.bmj.com/content/52/4/338

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Lung cancer (oncology) (670)
- Lung cancer (respiratory medicine) (670)
- Lung neoplasms (608)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/